ГоловнаArchive of numbers2022Volume 30, issue 1 (110)Protocol for the treatment of patients with amyotrophic lateral sclerosis using bone marrow stromal cells in the State Institution "Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine"
Title of the article Protocol for the treatment of patients with amyotrophic lateral sclerosis using bone marrow stromal cells in the State Institution "Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine"
Authors Voloshyna Natalia
Vasylovskyi Vitalii
Chernenko Maksym
In the section HELP TO PRACTICAL PHYSICIAN
Year 2022 Issue Volume 30, issue 1 (110) Pages 75-79
Type of article Scientific article Index UDK Index BBK -
Abstract DOI: https://doi.org/10.36927/2079-0325-V30-is1-2022-14
Key words
Access to full text version of the article pdf download
Bibliography 1. Voloshyna N. P., Yehorkina O. V., Haponov I. K., Horbunov O. V. Bichnyi amiotrofichnyi skleroz : naukovo-metodychne vydannia. Kyiv : Yevropa print, 2010. 32 s.
2. Egorkina O. V., Voloshina N. P., Gaponov I. K. Bokovoy amiotroficheskiy skleroz: osnovnyie sovremennyie napravleniya v lechenii. Mizhnarodniy nevrologichniy zhurnal. 2008. No. 6(22). S. 95—103. URL: http://www.mif-ua.com/archive/ article/7569.
3. Bokovoy amiotroficheskiy skleroz : rukovodstvo dlya vrachey / pod red. I. A. Zavalishina. Moskva : Evraziya, 2007. 447 s.
4. Voloshina N. P., Egorkina O. V. Diskussionnyie voprosyi terapii bokovogo amiotroficheskogo. Zhurnal NeyroNews. 2009. No. 6 (17). S. 15—17; No. 7(18). 2009. S. 21—25 (prodolzhenie).
5. Majoor-Krakauer D., Willems P. J., Hofman A. Genetic epidemiology of amyotrophic lateral. Clin. Genet. 2003. 63 (2). P. 83—101. DOI: 10.1046/j.0009-9163.2002.00001.x.
6. Skvortsova C. A., Limborskaya S. A., Sokolov K. B., Levitskiy G. H. Molekulyarnyie mehanizmyi razvitiya bolezni dvigatelnogo neyrona. Zhurnal nevrologii i psihiatrii im. C. C. Korsakova. 2005. T. 102. No. 4. C. 68—76.
7. Al-Chalabi A., Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013. 9(11). Р. 617—628. DOI: 10.1038/nrneurol.2013.203.
8. Vasenina E. E., Levin O. S. Okislitelnyiy stress v patogeneze neyrodegenerativnyih zabolevaniy: vozmozhnosti. Sovremennaya terapiya v psihiatrii i nevrologii. 2013. No. 3(4). S. 39—46.
9. A. E. King, Woodhouse A., Kirkcaldie M. T., Vickers J. C. Excitotoxicity in ALS: Overstimulation, or overreaction? Exp Neurol. 2016. 275. Pt 1. Р. 162—71. DOI: 10.1016/j.expneurol.2015.09.019.
10. Bräuer S., Zimyanin V., Hermann A. Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis. J Neural Transm (Vienna). 2018. 125(4). Р. 591—613. DOI: 10.1007/ s00702-018-1851-y.
11. Ramesh N., Pandey U. B. Autophagy dysregulation in ALS: When protein aggregates get out of hand. Front Mol Neurosci. 2017. 10. Р. 263. DOI: 10.3389/fnmol.2017.00263.
12. Hooten, K.G., Beers, D.R., Zhao, W. et al. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Appel Neurotherapeutics. 2015. 12(2). Р. 364—375. DOI: 10.1007/ s13311-014-0329-3.
13. Ugras S. E., Shorter J. RNA-binding proteins in amyotrophic lateral sclerosis and neurodegeneration. Neurol Res Int. 2012: 432780. DOI: 10.1155/2012/432780.
14. De Vos K. J., Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research? Neurobiol Dis. 2017. 105. Р. 283—299. DOI: 1016/j. nbd.2017.02.004.
15. Smith E. F., Shaw P. J., De K. J. The role of mitochondria in amyotrophic lateral sclerosis. Vos Neurosci Lett. 2017 Jun 30. DOI: 10.1016/j.neulet.2017.06.052.
16. Pittenger M. F., Mackay A. M., Beck S. C. et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999. 284. Р. 143—147. DOI: 10.1126/science.284.5411.143.
17. Blondheim NR, Levy YS, Ben-Zur T, Burshtein A, Cherlow T, Kan I, Barzilai R, Bahat-Stromza M, Barhum Y, Bulvik S, Melamed E, Offen D. Human mesenchymal stem cells express neural genes, suggesting a neural predisposition. Stem Cells Dev. 2006. 15. Р. 141—164. DOI: 10.1089/scd.2006.15.141.
18. Kassis I., Vaknin-Dembinsky A., Karussis D. Bone marrow mesenchymal stem cells: agents of immunomodulation and neuroprotection. Curr Stem Cell Res Ther. 2011. 6. Р. 63—68. DOI: 10.2174/157488811794480762.
19. Uccelli A., Pistoia V., Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol. 2007. 28. Р. 219—226. DOI: 10.1016/j.it.2007.03.001.
20. Ben-Hur T. Immunomodulation by neural stem cells. J Neurol Sci. 2008. 265. Р. 102—104. DOI: 10.1016/j.jns.2007.05.007.
21. Nauta A. J., Fibbe W. E. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007. 110. Р. 3499—3506. DOI: 10.1182/blood-2007-02-069716.
22. Kassis I., Grigoriadis N., Gowda-Kurkalli B. et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol. 2008. 65. Р. 753—761. DOI: 10.1001/archneur.65.6.753.
23. Zappia E., Casazza S., Pedemonte E. et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005. 106. Р. 1755—1761. DOI: 10.1182/blood-2005-04-1496.
24. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008. 8. Р. 726—736. DOI: 10.1038/nri2395.
25. Harris V. K., Yan Q. J., Vyshkina T. et al. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J Neurol Sci. 2012. 313. Р. 167—177. DOI: 10.1016/j.jns.2011.08.036.
26. Uccelli A., Laroni A., Freedman M. S. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol. 2011. 10. Р. 649—656. DOI: 10.1016/S1474-4422(11)70121-1.
27. Pluchino S., Quattrini A., Brambilla E. et al. Injection of adult neurospheres induces recovery in a chronic model  of multiple sclerosis. Nature. 2003. 422: 688—94. DOI: 10.1038/ nature01552.
28. Pluchino S, Gritti A, Blezer E, Amadio S, Brambilla E, Borsellino G, Cossetti C, Del Carro U, Comi G, ‘t Hart B, Vescovi A, Martino G. Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates. Ann Neurol. 2009. 66. Р. 343—354. DOI: 10.1002/ana.21745.
29. Ben-Hur T., Einstein O., Mizrachi-Kol R. et al. Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis. Glia. 2003. 41. Р. 73—80. DOI: 10.1002/glia.10159.
30. Karussis D., Petrou P., Kassis I. Clinical experience with stem cells and other cell therapies in neurological diseases. J Neurol Sci. 2013. 324. Р. 1—9. DOI: 10.1016/j.jns.2012.09.031.
31. J. Chen, Y. Li, L. Wang et al. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci. 2001. 189. Р. 49—57. DOI: 10.1016/s0022-510x(01)00557-3.
32. D. Karussis, C. Karageorgiou, A. Vaknin-Dembinsky et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010. 67. Р. 1187—1194. DOI: 10.1001/archneurol.2010.248.
33. P. H. Lee, J. E. Lee, H. S. Kim et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol. 2012. 72. Р. 32—40. DOI: 10.1002/ana.23612.
34. P. Petrou, Y. Gothelf, Z. Argov et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol. 2016. 73. Р. 337—344. DOI: 10.1001/jamaneurol.2015.4321.
35. J. D. Berry, M. E. Cudkowicz, A. J. Windebank et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, biomarker results. Neurology. 2019. 93. Р. 2294—2305. DOI: 10.1212/WNL.0000000000008620.
36. D. Karussis, I. Kassis, B. G. Kurkalli, S. Slavin, Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci. 2008. 265. Р. 131—135. DOI: 10.1016/j. jns.2007.05.005.
37. J. D. Glass, V. S. Hertzberg, N. M. Boulis et al. Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and 2 trials. Neurology. 2016. 87. Р. 392—400. DOI: 10.1212/WNL.0000000000002889.
38. Voloshina N. P., Vasilovskiy V. V., Mikulinskiy Yu. E., Schegelskaya E. A. Autoterapiya kletkami stromyi kostnogo mozga (KSKM), indutsirovannyimi v nervnyie, bolnyih s hronicheskimi zabolevaniyami TsNS (rasseyannyiy skleroz, bolezn Parkinsona). Ukrainskyi neirokhirurhichnyi zhurnal. 2003. No. 3. URL: https://cyberleninka.ru/article/n/autoterapiya-kletkamistromy-kostnogo-mozga-indutsirovannymi-v-nerv....
39. E. Eggenhofer, V. Benseler, A. Kroemer et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol. 2012. 3. Р. 297. DOI: 10.3389/fimmu.2012.00297.
40. Voloshyna N. P., Vasylovskyi V. V., Mikulynskyi Yu. Yu., Shchehelska O. A. / Patent UA 68711 A. «Sposib likuvannia khvorykh na rozsiianyi skleroz» vid 02.10.2003. Kyiv. Ukrpatent.
41. Voloshina N.P., Vasilovskiy V. V. Eticheskie voprosyi v lechenii bolnyih rasseyannyim sklerozom (autoterapiya stromalnyimi kletkami kostnogo mozga, indutsirovannyimi v nervnyie). Kultura narodov Prichernomorya. 2004. No. 56. T. 2. S. 185—186.
42. Karussis D., Kassis I. The potential use of stem cells in multiple sclerosis: an overview of the preclinical experience. Clin Neurol Neurosurg. 2008. 110. P. 889—896. DOI: 10.1016/j. clineuro.2008.02.008.
43. O. Fernandez, G. Izquierdo, V. Fernandez et al. Adiposederived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLoS ONE. 2018. 13: e0195891. DOI: 10.1371/journal. pone.0195891.
 44. S. Llufriu, M. Sepulveda, Y. Blanco et al Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS ONE. 2014. 9: e113936. DOI: 10.1371/journal.pone.0113936.
45. P. Petrou, Y. Gothelf Z. Argov et al. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. JAMA Neurol. 2016 Mar. 73(3). Р. 337—344. DOI: 10.1001/jamaneurol.2015.4321